SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC — Smyrna, Tennessee

SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC is a clinical research site located in Smyrna, Tennessee, United States 37167.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer.

Sponsors: Daiichi Sankyo.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Smyrna

Browse all research sites in Tennessee · View every site in Smyrna

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC?

SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC conducted?

SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC has 1 clinical trials on record, with 1 currently active. Their work covers HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer.

Is SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC accredited by Crixeo Clinical Trials?

SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.